Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b ...
Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate indication-spec ...
编者按：2026年美国临床肿瘤学会年会（ASCO ...
创新多组学队列研究学术论坛近日，美国威斯康星大学学者在期刊《Journal for ImmunoTherapy of Cancer》上发表了研究论文，题为“Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines ...
编者按：2026年美国临床肿瘤学会年会（ASCO ...
US FDA’s ODA committee recommends approval of AstraZeneca’s Truqap for PTEN-deficient metastatic hormone-sensitive prostate cancer: Cambridge, UK Monday, May 4, 2026, 17:00 Hr ...
MedPage Today on MSN
FDA panel endorses broader capivasertib use in prostate cancer
Agency staff expressed uncertainty over whether PFS benefit was "clinically meaningful" ...
Prostate cancer represents one of the most common malignancies in men in developed countries with increasing incidence in recent years due to the ...
The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)-a large-scale, phase III ...
TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果